Payment overview · 2025
General Payments
$1,334.61
114 reported records · 8 companies
Healthcare provider profile · identity verified
Deo M Peppersack, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · NAMPA, ID · NPI 1770538811
Verified facts
What the public records show
CMS Open Payments records show Deo M Peppersack, NP received $1,334.61 in general payments during 2025 across 114 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Asimtufii, Abilify Maintena, Caplyta, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Vraylar by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Caplyta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY ASIMTUFII as an associated drug or biological on 37017 records involving 12446 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Asimtufii by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $316.68 | 23.7% | 16 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $266.67 | 20.0% | 26 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $245.42 | 18.4% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $221.47 | 16.6% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $203.62 | 15.3% | 33 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $50.03 | 3.8% | 8 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.40 | 1.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.32 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,158.63 | 112 |
| Education | $175.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $266.67 | 26 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $221.47 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $161.50 | 8 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $155.18 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $142.66 | 28 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $88.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.96 | 5 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $50.03 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.93 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $40.89 | 6 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $19.81 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY ASIMTUFII abilify asimtufii |
2025 | Abilify Asimtufii | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 56 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 68 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
141 | 25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY ASIMTUFII open payments reported associated product |
CMS Open Payments — General Payments 37017 supporting records · 12446 recipient NPIs · example record 1227267748 |
Abilify Asimtufii · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lamotrigine | Lamotrigine | 251 | 45 |
| Trazodone Hcl | Trazodone Hcl | 229 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 219 | 32 |
| Aripiprazole | Aripiprazole | 180 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 143 | 22 |
| Vraylar | Cariprazine Hcl | 141 | 25 |
| Clonidine Hcl | Clonidine Hcl | 132 | 30 |
| Clonazepam | Clonazepam | 125 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 106 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 96 | 22 |
| Omeprazole | Omeprazole | 94 | 18 |
| Bupropion Xl | Bupropion Hcl | 82 | 22 |
| Invega Sustenna | Paliperidone Palmitate | 77 | 19 |
| Paliperidone Er | Paliperidone | 76 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 76 | 15 |
| Lorazepam | Lorazepam | 74 | 16 |
| Alprazolam | Alprazolam | 73 | 16 |
| Mirtazapine | Mirtazapine | 72 | 16 |
| Atomoxetine Hcl | Atomoxetine Hcl | 71 | suppressed |
| Lisinopril | Lisinopril | 70 | 16 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 69 | 18 |
| Olanzapine | Olanzapine | 68 | suppressed |
| Rexulti | Brexpiprazole | 68 | 14 |
| Gabapentin | Gabapentin | 63 | 22 |
| Meloxicam | Meloxicam | 59 | 13 |
| Abilify Maintena | Aripiprazole | 56 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 54 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 49 | 12 |
| Naltrexone Hcl | Naltrexone Hcl | 49 | suppressed |
| Caplyta | Lumateperone Tosylate | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 43 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 43 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 43 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 41 | suppressed |
| Risperidone | Risperidone | 40 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 40 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 39 | suppressed |
| Modafinil | Modafinil | 38 | suppressed |
| Clozapine | Clozapine | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 32 | 12 |
| Diazepam | Diazepam | 31 | suppressed |
| Olanzapine Odt | Olanzapine | 31 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Metformin Hcl | Metformin Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Spravato | Esketamine Hcl | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 22 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Abilify Asimtufii | Aripiprazole | 11 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,334.61 · 114 records | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AUSTEDO XR, Azstarys, CAPLYTA, FANAPT, INGREZZA, QULIPTA, Qelbree, REXULTI, UBRELVY, UZEDY, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Asimtufii play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error